Neuroleptic malignant syndrome: Difference between revisions

(46 intermediate revisions by 7 users not shown)
Line 1: Line 1:
==Background==
==Background==
*Life threatening neurologic emergency associated with the use of neuroleptic agents
*Life threatening neurologic emergency associated with the use of neuroleptic agents<ref>Su YP, Chang CK, Hayes RD, Harrison S, Lee W, Broadbent M, et al. Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatr Scand. Nov 15 2013</ref><ref>Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs. 2009;23(6):477-92</ref>
**Can occur with single dose, increasing dose, or same dose as usual
**Can occur with single dose, increasing dose, or same dose as usual <ref>Dunkley, E. J. C., Isbister, G. K., Sibbritt, D., Dawson, A. H. and Whyte, I. M. (2003) ‘The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity’, QJM, 96(9), pp. 635–642. doi: 10.1093/qjmed/hcg109</ref>
**May also occur with withdrawal of anti-Parkinson medication or use of antiemetics
**Most often seen with "typical" high potency antipsychotics ([[haloperidol]])
***also occurs with newer "atypicals" ([[risperidone]], [[olanzapine]])
***antiemetics ([[metoclopramide]], [[promethazine]])
***withdrawal of anti-Parkinson medication
*Develops over 1-3 days
*Develops over 1-3 days
*Majority of deaths occur from complications of muscle rigidity
*Majority of deaths occur from complications of muscle rigidity
*Mortality rates up to 5 to 20% <ref>Shalev A. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry. 1989;50(1):18-25.</ref>


==Clinical Features==
==Clinical Features==
*Tetrad of:
*Tetrad of:<ref>Gurrera RJ, Velamoor V, Cernovsky ZZ. A Validation Study of the International Consensus Diagnostic Criteria for Neuroleptic Malignant Syndrome. J Clin Psychopharmacol. Aug 22 2013</ref>
#Altered Mental Status
**[[Altered mental status]] - Agitated delirium progressing to stupor/coma
##Agitated delirium progressing to stupor/coma
**Muscular Rigidity - Generalized, "lead pipe" rigidity
#Muscular Rigidity
**[[Hyperthermia]] >38C (87%); >40C (40%)
##Generalized, "lead pipe" rigidity
**Autonomic Instability - Tachycardia, Hypertension, Diaphoresis
#Hyperthermia
##>38C (87%)
##>40C (40%)
#Autonomic Instability
##Tachycardia
##Hypertension
##Diaphoresis


==DDX==
==Differential Diagnosis==
#[[Serotonin Syndrome]]
*[[Serotonin Syndrome]]
##More likely to have hyperreflexia, myoclonus, ataxis, N/V, diarrhea
**More likely to have hyperreflexia, myoclonus, ataxis, nausea and vomiting, diarrhea
##Rigidity and hyperthermia, if present, is less severe than in NMS
**Rigidity and hyperthermia, if present, is less severe than in NMS
#[[Malignant Hyperthermia]]
*[[Malignant Hyperthermia]]
##Distinguish by clinical setting (use of inhalational anesthetics or sux)
**Distinguish by clinical setting (use of inhalational anesthetics or sux)
##Hyperthermia, muscle rigidity, and dysautonomia is similar to NMS though more fulminant
**Hyperthermia, muscle rigidity, and dysautonomia is similar to NMS though more fulminant
#Anticholinergic Toxidrome
*[[Anticholinergic Toxicity]]
##Diaphoresis, rigidity, elevated CK are absent
**Diaphoresis, rigidity, elevated CK are absent
##Flushing, mydriasis, bladder distension are common
**Flushing, mydriasis, bladder distension are common
#Sympathomimetics
*[[Sympathomimetics]]
##Rigidity is not seen
**Rigidity is not seen
#Meningitis/encephalitis
#Delirium Tremens
#Heat Stroke


==Work-Up==
{{AMS and fever DDX}}
#Total CK
##Typically >1000
##Correlates with degree of rigidity
#CBC
##WBC >10K is typical
#Chemistry
##May show hypocalcemia, hypomagnesemia, hyperkalemia, metabolic acidosis
#UA
##Myoglobinuria (from rhabdo)
#LFT
##Transaminitis
#CT/LP
##CSF may have mildly elevated protein


==Treatment==
==Evaluation==
#Stop causative agent
===Workup===
##If precipitant is discontinuation of dopaminergic therapy, it should be restarted
*Total CK
#Supportive Care
**Typically >1000
##Fluid resuscitation
**Correlates with degree of rigidity
##Cooling measures
*CBC
###Consider paralysis with nondepolarizing agents
**WBC >10K is typical
##Agitation control with benzos
*Chemistry
##Blood pressure control with clonidine or nitroprusside
**May show hypocalcemia, hypomagnesemia, hyperkalemia, metabolic acidosis
#Medical therapy<ref>Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry. Aug 1987;22(8):1004-20 </ref>
*[[Urinalysis]]
##Controversial; efficacy is unclear and disputed
**Myoglobinuria (from rhabdo)
###Dantrolene
*LFT
####Skeletal muscle relaxant; may cause hepatotoxicity in pts w/ liver disease
**Transaminitis
####Consider only in pts with severe rigidity
*CT/[[LP]]
####Give 0.25-2mg/kg IV q6-12hr
**CSF may have mildly elevated protein
###Bromocriptine
 
####Dopamine agonist
{{Serotonin syndrome vs neuroleptic malignant syndrome}}
####Give 2.5mg NG q6-8hr
 
###Amantadine
==Management==
####Alternative to bromocriptine
*The causative agent should be stopped
####Give 100mg PO/NG initially; titrate up as needed to max dose 200mg q12hr
*If precipitant is a dopaminergic therapy (L-dopa or Carbidopa) it can be restarted later at lower doses as an outpatient
###ECT
 
===Supportive Care===
*Agitation should be controlled with [[Benzodiazepines]]
*[[Fluid resuscitation]]
*Cooling measures
*Intubation and paralysis for severe cases, chest wall rigidity or respiratory failure
 
===Directed Medical Therapy<ref>Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry. Aug 1987;22(8):1004-20 </ref>===
''Controversial with unclear and disputed efficacy''
*[[Dantrolene]] (skeletal muscle relaxant) - Consider only in patients with severe rigidity
**May cause hepatotoxicity in patients with liver disease
**0.25-2mg/kg IV q6-12hr, max dose 10mg/kg/day
*[[Bromocriptine]] (dopamine agonist)
**2.5mg PO q6-8hr, max dose 40mg/day
*[[Amantadine]] (alternative to bromocriptine)
**100mg PO initially; titrate up as needed to max dose 200mg q12hr
 
==Disposition==
*Admit, usually to ICU


==Complications==
==Complications==
#Dehydration
*Dehydration
#Electrolyte imbalance
*[[Electrolyte imbalance]]
#ARF (rhabdo)
*[[Acute renal failure]] ([[rhabdomyolysis]])
#Dysrhythmias  
*[[Dysrhythmias ]]
#ACS
*[[ACS]]
#Respiratory failure
*[[Respiratory failure]]
##Chest wall rigidity, aspiration PNA, PE
**Chest wall rigidity, aspiration [[pneumonia]], [[PE]]
#DIC
*[[DIC]]
#Seizure (hyperthermia, electrolyte derangements)
*[[Seizure]] ([[hyperthermia]], [[electrolyte derangements]])
#Hepatic failure
*[[Hepatic failure]]
#Sepsis
*[[Sepsis]]
 
==See Also==
 


==Source==
==References==
<references>
<references/>


[[Category:Psych]]
[[Category:Psychiatry]]
[[Category:Tox]]
[[Category:Toxicology]]

Revision as of 03:40, 12 October 2018

Background

  • Life threatening neurologic emergency associated with the use of neuroleptic agents[1][2]
  • Develops over 1-3 days
  • Majority of deaths occur from complications of muscle rigidity
  • Mortality rates up to 5 to 20% [4]

Clinical Features

  • Tetrad of:[5]
    • Altered mental status - Agitated delirium progressing to stupor/coma
    • Muscular Rigidity - Generalized, "lead pipe" rigidity
    • Hyperthermia >38C (87%); >40C (40%)
    • Autonomic Instability - Tachycardia, Hypertension, Diaphoresis

Differential Diagnosis

  • Serotonin Syndrome
    • More likely to have hyperreflexia, myoclonus, ataxis, nausea and vomiting, diarrhea
    • Rigidity and hyperthermia, if present, is less severe than in NMS
  • Malignant Hyperthermia
    • Distinguish by clinical setting (use of inhalational anesthetics or sux)
    • Hyperthermia, muscle rigidity, and dysautonomia is similar to NMS though more fulminant
  • Anticholinergic Toxicity
    • Diaphoresis, rigidity, elevated CK are absent
    • Flushing, mydriasis, bladder distension are common
  • Sympathomimetics
    • Rigidity is not seen

Altered mental status and fever

Evaluation

Workup

  • Total CK
    • Typically >1000
    • Correlates with degree of rigidity
  • CBC
    • WBC >10K is typical
  • Chemistry
    • May show hypocalcemia, hypomagnesemia, hyperkalemia, metabolic acidosis
  • Urinalysis
    • Myoglobinuria (from rhabdo)
  • LFT
    • Transaminitis
  • CT/LP
    • CSF may have mildly elevated protein

Serotonin syndrome vs Neuroleptic malignant syndrome

  • History of a new serotonergic drug or a dose increase of a serotonergic drug are helpful
  • Serotonin syndrome is usually much more acute in onset than NMS which may develop over days or weeks
  • Presence of ‘lead pipe’ rigidity is typical of NMS, while serotonin syndrome typically manifests with tremor and hyperreflexia
  • Elevations in CK, LFTs, and WBC, coupled with a low iron level, distinguishes NMS from serotonin syndrome among patients taking both neuroleptic and serotonin agonist medications simultaneously

Management

  • The causative agent should be stopped
  • If precipitant is a dopaminergic therapy (L-dopa or Carbidopa) it can be restarted later at lower doses as an outpatient

Supportive Care

  • Agitation should be controlled with Benzodiazepines
  • Fluid resuscitation
  • Cooling measures
  • Intubation and paralysis for severe cases, chest wall rigidity or respiratory failure

Directed Medical Therapy[6]

Controversial with unclear and disputed efficacy

  • Dantrolene (skeletal muscle relaxant) - Consider only in patients with severe rigidity
    • May cause hepatotoxicity in patients with liver disease
    • 0.25-2mg/kg IV q6-12hr, max dose 10mg/kg/day
  • Bromocriptine (dopamine agonist)
    • 2.5mg PO q6-8hr, max dose 40mg/day
  • Amantadine (alternative to bromocriptine)
    • 100mg PO initially; titrate up as needed to max dose 200mg q12hr

Disposition

  • Admit, usually to ICU

Complications

See Also

References

  1. Su YP, Chang CK, Hayes RD, Harrison S, Lee W, Broadbent M, et al. Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatr Scand. Nov 15 2013
  2. Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs. 2009;23(6):477-92
  3. Dunkley, E. J. C., Isbister, G. K., Sibbritt, D., Dawson, A. H. and Whyte, I. M. (2003) ‘The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity’, QJM, 96(9), pp. 635–642. doi: 10.1093/qjmed/hcg109
  4. Shalev A. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry. 1989;50(1):18-25.
  5. Gurrera RJ, Velamoor V, Cernovsky ZZ. A Validation Study of the International Consensus Diagnostic Criteria for Neuroleptic Malignant Syndrome. J Clin Psychopharmacol. Aug 22 2013
  6. Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry. Aug 1987;22(8):1004-20